|drug2087||Motivational telephone intervention Wiki||1.00|
There is one clinical trial.
COVID-19 pandemic is currently affecting the globe. To date, there is no effective oral therapy against SARS-CoV2 infection. The investigators propose to test as a repurposing drug combination, a short course of tenofovir disoproxil and emtricitabine (TDF/FTC), as a proof-of-concept randomized open-label study to test its viral efficacy against SARS-CoV2.
Description: Nasopharyngeal swab performed at baseline and day-4 with RT-PCR for SARS-CoV2Measure: Phase 2B: Reduction of SARS-CoV2 viral load assessed by Ct PCR at day-4 adjusted on Ct PCR SARS-CoV2 viral load at baseline (ANCOVA) Time: Day-4 after the start of study
Description: Nasopharyngeal swab performed at day-4 with RT-PCR for SARS-CoV2Measure: Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-4 with Ct > or = 28 Time: Day-4 after the start of study
Description: Number of adverse events according to the CTCAE gradeMeasure: Phase 2B/3: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Time: From the start of the study to Day-7
Description: Self-reported COVID-19 related symptomsMeasure: Phase 3: Symptoms score Time: From the start of the study to Day-7
Description: Assessed by investigators up to day-15Measure: Phase 3: Proportion of secondary hospitalization Time: Day-15
Description: Nasopharyngeal swab performed at day-7 with RT-PCR for SARS-CoV2Measure: Phase 3: Rate of non-contagious nasopharyngeal sample for SARS-CoV2 by PCR on Day-7 with Ct > or = 28 Time: Day-7 after the start of study
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports